Immix Biopharma, Inc.
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing CAR-T cell therapies for AL amyloidosis and other serious diseases. Its lead program, NXC-201, is in Phase 1b/2 clinical testing in the U.S. and ex-U.S., with orphan drug designations from both the FDA and European Commission.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of NXC-201, a CAR-T therapy targeting AL amyloidosis and other serious diseases.
Execution of U.S. and ex-U.S. clinical studies to generate safety and efficacy data.
Manufacturing of product candidates for trials, regulatory readiness, and eventual commercialization.
Patent prosecution, licensing, and development of additional product candidates or technologies.
Asiakkaat
Immix Biopharma does not sell commercial products yet; its immediate counterparties are clinical trial sites, investigators, suppliers, and grant/capital providers that fund development. If approved, the eventual customers would be hospitals, treatment centers, and patients with AL amyloidosis or other serious diseases treated through specialty oncology/hematology channels.
Patients with AL amyloidosis enrolled in NEXICART-1 and NEXICART-2 to evaluate safety and efficacy.
Hospitals and research centers that administer the studies and generate regulatory-grade data.
Hospitals and infusion centers that could use NXC-201 if it receives regulatory approval.
Public and private funding sources that finance R&D, manufacturing, and regulatory work.
Strategia
The company’s strategy is to advance NXC-201 through clinical development, secure regulatory support, and build the manufacturing and operational capabilities needed for eventual commercialization. It is also pursuing external funding, including grants and equity financing, to support a capital-intensive development path while expanding its intellectual property and pipeline optionality.
Clinical data is the main value driver for a pre-revenue cell therapy company.
Regulatory designations can improve development efficiency and market access prospects.
Cell therapies require specialized supply chain and manufacturing scale before launch.
Maantiede
Immix Biopharma is headquartered in the United States and runs its lead clinical program in both the U.S. and ex-U.S. settings. The company also disclosed an Australian subsidiary for tax purposes and received a CIRM grant tied to U.S.-based clinical development, so its operating footprint is still concentrated around development activities rather than commercial sales.
Riskit
Immix Biopharma is exposed to the typical risks of a clinical-stage biotech: trial failure, regulatory delay, and the need to raise capital before any product revenue exists. Its disclosures also highlight going-concern risk, dependence on external funding, and the high cost of manufacturing, IP protection, and public-company operations.
- Ability to continue as a going concernVaikutus: KriittinenTodennäköisyys: Korkea
The company has recurring losses, negative operating cash flow, and depends on external capital and grants.
Kohdistuu: Pre-revenue development-stage operations
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
NXC-201 is still in early-stage trials, so safety or efficacy issues could halt development.
Kohdistuu: NEXICART-1 and NEXICART-2
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Approval depends on trial outcomes and regulator review, which can be delayed or denied.
Kohdistuu: FDA and EMA pathways
- Capital raising and dilutionVaikutus: KorkeaTodennäköisyys: Korkea
The business is funded primarily through equity offerings and grant reimbursements.
Kohdistuu: Future financings
- Manufacturing and scale-up executionVaikutus: Keskitaso
Cell therapy production is complex and costly, especially before commercial launch.
Kohdistuu: Clinical supply and future commercial readiness
Kirjanpito
Harkinnanvaraiset erätClinical trial and manufacturing spend can shift materially by quarter, driving loss volatility.
Vaikutus: Affects operating loss and comparability across periods
CIRM reimbursements are recognized as received or earned under the grant terms and offset development costs.
Vaikutus: Affects other income and net cash burn
Management explicitly cites valuation of intangible and long-lived assets as a key estimate.
Vaikutus: Potential impairment charges if program value weakens
The company currently has no meaningful commercial sales, so any future revenue will depend on approval and contract terms.
Vaikutus: Could materially change reported results once commercialization begins
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Nurix Therapeutics, Inc.
NRIX · Pharmaceutical Preparations
Nurix Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degradation medicines.
Päivitetty: 24.9.2026